

## INTERIM REPORT – Extract from the official Swedish report

1 January – 30 June 2017  
(NGM: LIFE B)



### Financial information

#### Group

- Net sales for the period January – June 2017 totals 3 369 (3 978) kSEK
- Profit after taxes totals – 10 057 (-9 271) kSEK.
- Profit per share was – 0,01 (-0,01) kr.

#### Parent company

- Net sales for the period January – June 2017 totals 3 352 (3 978) kSEK.
- Profit after taxes totals – 8 592 (-8 830) kSEK.
- Profit per share was – 0,005 (-0,01) SEK.



*LifeAssays® AB's business idea is to develop, manufacture and sell diagnostic systems based on the company's own and patented technology MagnetoImmunoAssay (MLA). The company delivers safe and robust systems for quick and reliable analysis in veterinary medicine. The company's patented products consist of instruments and disposable reagent which is harmless to patients, staff and the environment. Alternative markets for the company's products are in human medicine as well as food and pharmaceutical industries.*

## CEO comments

### Second quarter 2017

- Net sales for the Group as well during the quarter was 1 778 kSEK which is an increase by 11% over the first quarter 2017.
- During the second quarter, the formation of our company in China, co-owned with St. Grand, progressed according to plan. We have selected premises in Qingdao and the company's name is determined to Qingdao Lai Fu Ai Sheng Medical Technology Ltd. The company is expected to become operational in Q3.
- Instrument sales to China continues to be strong. 50 systems were delivered at the end of the second quarter and most of these systems are already available to customers.
- The sales of our new cat test has developed very positively, in particular in the Nordic market where it has contributed to the sales value of cat tests being 66% higher than in the first quarter.
- A test for the acute phase protein Serum Amyloid A (SAA) for horses was developed during the second quarter up to validation. External evaluations are performed in Germany during July and August.
- A highly focused effort in Germany was carried out at the end of the second quarter with the intention of strengthening sales channels. Sales start is expected to start after the holiday season.
- The extra resources we could add to the United States with the help of funds from the Swedish Agency for Growth in Skåne include being able to attend an exhibition in our own name, contracting a representative and "independent reps" and accelerated discussions with a number of potential distributors.
- The project with our unique disposable test is still in line with the original schedule. In the second quarter, the project has also made great progress with an integrated sampling unit to enable easier and more accurate sampling and thus increased user friendliness and precision in the results.

18<sup>th</sup> of August 2017

Anders Ingvarsson, MSc

VD för LifeAssays AB

[anders.ingvarsson@lifeassays.com](mailto:anders.ingvarsson@lifeassays.com)

## Share information & owner structure

The share price (last transaction) for the quarter was 0,034 (0,025) SEK, which gives a market cap of 71.3 (36.2) mSEK. The nominal value is 0,02 kr.

The average number of shares for the period was 1 728 355 018 shares.

<b>Largest owners 30th of June 2017</b>	<b>No of shars</b>	<b>Votes/capital</b>
Tibia Konsult AB	185 694 934	8,86%
Biothom Oy	144 811 908	6,91%
Avanza Pension	111 352 738	5,31%
Matz Eklund	64 150 440	3,06%
Peter Schlein-Andersen	61 050 000	2,91%
Nordnet Pensionsförsäkring AB	54 333 985	2,59%
Svenska Handelsbanken Markets	51 478 296	2,46%
Bo Göran Åkerlund	47 200 000	2,25%
Christian Borgvall	26 000 000	1,24%
AN Holding	24 000 000	1,15%
Övriga	1 325 664 870	63,26%
<b>Summa</b>	<b>2 095 737 171</b>	<b>100,00%</b>

## Outstanding warrants

There are currently no outstanding warrants.

## Significant events after the end of the quarter

No significant events has occurred after the end of the quarter.

## Financial calendar

Q3 report 2017                      27<sup>th</sup> October 2017  
Q4 report 2017                      February 2018

This report has not been audited by the company auditors.

### Contact information:

LifeAssays® AB, Sölvegatan 43A, 223 70 LUND, tel +46 46-286 5400, fax +46 46-286 5419  
Web: [www.lifeassays.com](http://www.lifeassays.com), epost: [info@lifeassays.com](mailto:info@lifeassays.com)

For further information contact CEO of LifeAssays AB, Anders Ingvarsson, telephone +46 46-286 54 00 or email: [info@lifeassays.com](mailto:info@lifeassays.com)

## Condensed statement of comprehensive income - Gruop

TSEK	2017 Apr-Jun	2016 Apr-Jun	2017 Jan-Jun	2016 Jan-Jun	2016 Jan-Dec
<b>Net sales</b>					
Net sales	1 778	2 187	3 369	3 978	7 456
Other income	12	46	52	54	111
<b>Total net sales</b>	<b>1 790</b>	<b>2 233</b>	<b>3 421</b>	<b>4 032</b>	<b>7 567</b>
<b>Operating expenses</b>					
Raw materials and consumables	-677	-1 026	-1 246	-1 801	-3 231
Other external expenses	-2 871	-2 580	-5 156	-4 916	-9 131
Personnel expenses	-3 139	-3 296	-6 079	-6 056	-12 367
Depreciation and writedowns of intangible and tangible assets	-424	-168	-821	-329	-1 586
Other operating income/cost					
<b>Total operating expenses</b>	<b>-7 111</b>	<b>-7 070</b>	<b>-13 302</b>	<b>-13 102</b>	<b>-26 315</b>
<b>Operating profit/loss</b>	<b>-5 321</b>	<b>-4 837</b>	<b>-9 881</b>	<b>-9 070</b>	<b>-18 748</b>
<b>Profit /loss from financial activities</b>					
Interest income	43	25	19	43	54
Interest expenses	-128	-85	-182	-172	-351
<b>Profit before taxes</b>	<b>-5 406</b>	<b>-4 897</b>	<b>-10 044</b>	<b>-9 199</b>	<b>-19 045</b>
Taxes	-10	-38	-13	-72	18
<b>Profit/loss for the period</b>	<b>-5 416</b>	<b>-4 935</b>	<b>-10 057</b>	<b>-9 271</b>	<b>-19 027</b>
<b>TSEK</b>	<b>2017 Apr-Jun</b>	<b>2016 Apr-Jun</b>	<b>2017 Jan-Jun</b>	<b>2016 Jan-Jun</b>	<b>2016 Jan-Dec</b>
Profit/loss for the period	-5 416	-4 935	-10 057	-9 271	-19 027
Items that may be reclassified to the income statement:					
Translation differences	3	4	1	147	-14
<b>Total comprehensive income for the period</b>	<b>-5 413</b>	<b>-4 931</b>	<b>-10 056</b>	<b>-9 124</b>	<b>-19 041</b>
<b>Key ratios:</b>					
Earnings per share before and after dilution	-0,003	-0,01	-0,01	-0,01	-0,02
Average number of shares	1 944 390 370	756 653 786	1 728 355 018	751 299 639	1 199 765 939
Number of shares at the end of the period	2 095 737 171	1 448 911 506	2 095 737 171	1 448 911 506	1 656 343 234

## Condensed consolidated balance sheet - Group

TSEK	2017-06-30	2017-06-30	2016-12-31
<b>Assets</b>			
<b>Fixed assets</b>			
Intangible fixed assets	21 710	18 784	19 266
Tangible assets	423	504	459
<b>Total fixed assets</b>	<b>22 133</b>	<b>19 288</b>	<b>19 725</b>
<b>Current assets</b>			
Inventories	1 950	1 684	1 830
Other current assets	3 274	3 506	2 889
Liquid assets, including current investments	9 121	13 377	8 472
<b>Total current assets</b>	<b>14 345</b>	<b>18 567</b>	<b>13 191</b>
<b>Total assets</b>	<b>36 478</b>	<b>37 855</b>	<b>32 916</b>
<b>Liabilities and shareholders equity</b>			
Share capital	41 915	28 978	33 127
Other capital contributed	145 430	127 896	141 262
Reserves	268	85	85
Profit/Loss brought forward	-156 873	-124 380	-137 846
Total comprehensive income for the period	-10 056	-9 271	-19 027
<b>Total equity</b>	<b>20 684</b>	<b>23 308</b>	<b>17 601</b>
<b>Long term liabilities</b>			
	10 207	9 072	9 763
Deferred tax liabilities	2 076	2 113	2 022
<b>Total long-term liabilities</b>	<b>12 283</b>	<b>11 185</b>	<b>11 785</b>
<b>Current liabilities</b>			
Other current liabilities	3 511	3 362	3 530
<b>Total current liabilities</b>	<b>3 511</b>	<b>3 362</b>	<b>3 530</b>
<b>Total liabilities and shareholders equity</b>	<b>36 478</b>	<b>37 855</b>	<b>32 916</b>

## Consolidated Cash flow statement - Group

TSEK	2017 Apr-Jun	2016 Apr-Jun	2017 Jan-Jun	2016 Jan-Jun	2016 Jan-Dec
<b>Operating activities</b>					
Operating profit/loss	-5 321	-4 837	-9 881	-9 070	-18 748
Interest received	43	25	19	43	54
Interest paid	-127	-32	-182	-65	-351
Other items not included in cash flow	494	136	938	333	1 759
<b>Cash flow from operating activities before changes in working capital</b>	<b>-4 911</b>	<b>-4 708</b>	<b>-9 106</b>	<b>-8 759</b>	<b>-17 286</b>
Change in operating receivables	-89	90	-120	440	294
Change in inventory	-12	-736	-384	-1 231	-592
Change in operating liabilities	442	-111	181	291	493
<b>Cash flow from operating activities</b>	<b>-4 570</b>	<b>-5 465</b>	<b>-9 429</b>	<b>-9 259</b>	<b>-17 091</b>
<b>Investment activities</b>					
Intangible assets	-2 395	-551	-3 018	-1 053	-2 702
Fixed assets	-14	-45	-14	-279	-322
<b>Total cash flow from investment activities</b>	<b>-2 409</b>	<b>-596</b>	<b>-3 032</b>	<b>-1 332</b>	<b>-3 024</b>
<b>Financing activities</b>					
New share issue	13 094	18 296	12 956	18 296	22 344
Change in financial receivables	-73	0	153	0	570
<b>Cash flow from financing activities</b>	<b>13 021</b>	<b>18 296</b>	<b>13 109</b>	<b>18 296</b>	<b>22 914</b>
<b>Cash flow for the period</b>	<b>6 042</b>	<b>12 235</b>	<b>648</b>	<b>7 705</b>	<b>2 799</b>
Liquid assets at the beginning of the period	3 076	1 134	8 472	5 659	5 659
Exchange rate difference liquid assets	3	8	1	13	14
Cash flow for the period	6 042	12 235	648	7 705	2 799
<b>Liquid assets at the end of the period</b>	<b>9 121</b>	<b>13 377</b>	<b>9 121</b>	<b>13 377</b>	<b>8 472</b>

Key ratios - Group	2 017 Apr-Jun	2016 Apr-Jun	2 017 Jan-Jun	2016 Jan-Jun	2016 Jan-Dec
Equity/asset ratio (%)	57%	62%	57%	62%	53%
Return on equity	neg	neg	neg	neg	neg
Profit/loss after finance net (TSEK)	-5 406	-4 897	-10 044	-9 199	-19 045
Profit/loss per share (sek/share)	-0,003	-0,01	-0,02	-0,05	-0,06
Cash flow (TSEK)	6 042	12 235	648	7 705	2 799

## Consolidated changes in shareholders equity

TSEK	Share capital	Other capital contributed	Reserves	Profit/loss brought forward	Profit/loss for the year	Shareholders equity
<b>Opening balance</b>	33 127	141 262	85	-137 846	-19 027	17 601
Disposition of previous years' result				-19 027	19 027	0
Ongoing share issue						0
Reduction of share capital						0
Share issue	8 788	4 168				12 956
Redemption of warrants						0
Translation difference group companies			183			183
Profit/loss for the year					-10 056	-10 056
<b>Closing balance</b>	<b>41 915</b>	<b>145 430</b>	<b>268</b>	<b>-156 873</b>	<b>-10 056</b>	<b>20 684</b>

## Segment information

Split of Net sales per product group	2017 Apr-Jun	2016 Apr-Jun	2017 Jan-Jun	2016 Jan-Jun	2016 42735
Tester	1456	1806	2865	3 296	6342
Instrument	252	261	396	428	868
Övrigt	58	120	91	254	245
<b>Total</b>	<b>1 766</b>	<b>2 187</b>	<b>3 352</b>	<b>3 978</b>	<b>7 455</b>

Net sales per region (Split based on where the customers are established)	2017 Apr-Jun	2016 Apr-Jun	2017 Jan-Jun	2016 Jan-Jun	2016 42735
Nordic	1 256	1 157	2 325	2 372	4 879
Europé	34	39	77	62	453
North America	0	5	0	12	19
Asia	476	986	950	1 532	2 104
<b>Total</b>	<b>1 766</b>	<b>2 187</b>	<b>3 352</b>	<b>3 978</b>	<b>7 455</b>